Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.64 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.64 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.64 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541598 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL13541628 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL19229983 | 0.97 | LGALS3 (0.63) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL23059816 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL23059762 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL12356371 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL12197053 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL15176952 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL21180415 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL16312015 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4CD69CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263858-A1 | Process for synthesis of mucin-type peptides and muc1-related glycopeptides | SHIONOGI & CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1801118-A1 | PROCESS FOR SYNTHESIS OF MUCIN-TYPE PEPTIDES AND MUC1-RELATED GLYCOPEPTIDES | SHIONOGI & CO., LTD. (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263858-A1 | Process for synthesis of mucin-type peptides and muc1-related glycopeptides | MUC1, VIP, TMPRSS15 | LGALS3 274/4885LGALS8 404/4885LGALS4 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.